上海赛远生物科技

Shanghai Cell-Far Biotechnology is a clinical-stage biotechnology company and a key subsidiary of CARsgen Therapeutics, specializing in the development of chimeric antigen receptor T-cell (CAR-T) therapies. The company focuses on addressing unmet medical needs in solid tumors, particularly liver, gastric, and pancreatic cancers, by targeting antigens like Glypican-3 and Claudin 18.2. Cell-Far utilizes advanced genetic engineering to enhance the efficacy and persistence of T-cells within the immunosuppressive tumor microenvironment. Its research contributes significantly to a robust pipeline of next-generation immunotherapies currently in various stages of clinical trials. The company operates state-of-the-art R&D facilities in Shanghai to support its mission of providing curative cell therapies for cancer patients.